5 min read
A regulatory team that has taken a biologic through EMA review arrives in Brazil with something real: a documented approval from one of the most rigorous agencies in the world. When ANVISA’s reliance framework enters the conversation — formalized under RDC 741/2022 and operative since April 2024 — the conclusion almost writes itself. The hard work is done. The passport exists. Brazil has a mechanism to use it.
That conclusion is not wrong. It is just missing a few stamps.
Reliance, as ANVISA defines it, is a procedural framework that allows the agency to use a foreign regulatory assessment as reference material in its own decision-making process. It does not transfer the conclusions of that assessment. It does not inherit the approval. What it does is open a structured pathway — one that still runs on ANVISA’s own terms, with ANVISA’s own conditions attached. The distinction is not bureaucratic. It is the difference between a pathway that accelerates a well-prepared submission and one that stalls a submission that arrived assuming the preparation was already complete.
STAMP 01 — ENTRY
Reliance lets you cross. It does not define what ANVISA will find on the other side.
The entry stamp is the one most teams believe they already have. An EMA or FDA approval qualifies a product for the reliance pathway under ANVISA’s framework — that part is real and well-established in the regulation. What it does not do is pre-answer the questions ANVISA is independently designed to ask. The agency retains full authority to reach its own conclusions about a product’s suitability for the Brazilian market, regardless of what any reference authority determined. Reliance is a starting point for ANVISA’s evaluation. It is not a substitute for it.
That distinction matters more in biologics than in almost any other category — because biologics are not simply transferred between markets, they are reproduced in specific manufacturing conditions. And reproduction introduces variables that a foreign approval, however rigorous, was never asked to evaluate for Brazil.
STAMP 02 — EQUIVALENCE
The product EMA approved and the product Brazil will evaluate are not automatically the same product under ANVISA’s criteria.
This is where the gap becomes structural rather than procedural. ANVISA’s product equivalence conditions — the requirements that establish whether a biologic submitted for registration in Brazil is genuinely comparable to the reference product recognized by the reliance framework — do not disappear because a foreign agency already ran a comparability exercise. They apply independently, under Brazilian regulatory logic, with Brazilian reference standards.
For biosimilar developers, this is the precise point where a program built to perform in one regulatory environment begins to show its edges in another. The comparability data exists. The clinical evidence exists. What may not exist is the specific demonstration of equivalence that ANVISA’s framework requires — not because the product is different, but because the question being asked is. RDC 875/2024 introduced updates to the comparability pathway that expand what can be waived when scientifically justified — but those waivers are conditional on meeting ANVISA’s own evidentiary standards, not on having cleared a prior agency’s bar.
It is worth noting that ANVISA is actively working to reduce processing times for biological products — a backlog reduction initiative launched in 2025 has already shown measurable progress in post-registration petitions, and structural measures approved in November 2025 (RDC 997/2025) created a dedicated priority queue for submissions that qualify under the reliance pathway. That queue is a real advantage. But accessing it depends on meeting the equivalence and documentation conditions that make a submission eligible — which is exactly what needs to be confirmed before planning begins.
STAMP 03 — MANUFACTURING
GMP Transfer does not disappear because a foreign approval already exists. It is a condition of the territory, not a legacy of the origin.
What this does not eliminate is the need to confirm that the specific manufacturing site seeking authorization to supply the Brazilian market meets ANVISA’s own GMP requirements for that purpose. The recognition framework reduces duplication — it does not remove the site-level verification step. For global teams managing biologics portfolios across multiple markets, what is sometimes underestimated is the specificity of documentation and coordination that ANVISA requires at the site level — work that does not automatically follow from a European GMP certification and belongs in the submission timeline before that timeline is presented to any stakeholder.
STAMP 04 — QUALITY DOSSIER
RDC 875/2024 has its own quality logic. It does not inherit it from any reference agency.
This is not a translation problem. A quality dossier built to answer EMA’s questions is rigorous, well-constructed, and built to a standard that has performed under serious scrutiny. The issue is not the quality of what was built. It is whether what was built answers the questions ANVISA is actually asking. Those are related questions — but they are not the same question, and in biologics, the distance between them is where most dossier gaps originate.
Where the territory stops matching the document
A structural gap in a biologics submission does not announce itself clearly. It moves — into timelines, into query responses, into the internal conversations that happen when a market entry that was supposed to be the next logical step becomes something that requires renegotiation.
The challenge is not that global teams arrive unprepared. Most don’t. The challenge is that the preparation they bring was optimized for a different set of conditions. And in a regulatory process where the window between submission and first response is already measured in months, discovering that misalignment mid-process is a different problem than discovering it before the process begins.
STAMP 05 — VERIFICATION
The passport is complete when the four previous stamps are confirmed — not when submission planning begins.
The teams that move through ANVISA’s biologics reliance pathway most efficiently are not always the ones with the strongest global track record. They are the ones that understood, early enough, that Brazil requires a specific reading of their program — and that the right moment to develop that reading is before the process begins, not during it.
That window exists. It is not unlimited. A submission that enters the reliance pathway with unresolved equivalence conditions, incomplete GMP documentation, or a quality dossier built for a different agency’s framework does not fail immediately. It accumulates delays — at the points in the process where ANVISA’s questions meet answers that were designed for someone else’s review.
The biological passport is a real document. The reliance framework is a real pathway, with real advantages for submissions that arrive ready to use it. What determines whether that pathway moves is the verification that happens before submission planning locks in — the honest assessment of which stamps are already there, and which ones still need to be earned.
If your team is evaluating Brazil as part of a biologics portfolio expansion and wants to understand where your current program stands against ANVISA’s conditions, Freyr’s regulatory team works through exactly that kind of assessment — before the process begins.
